Detection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease.

[1]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[2]  M. Neurath,et al.  Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. , 2018, Journal of Crohn's & colitis.

[3]  Christopher F. Martin,et al.  Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. , 2018, Gastroenterology.

[4]  A. Shitrit,et al.  Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[5]  J. Borrás-Blasco,et al.  Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature , 2017, Journal of clinical pharmacy and therapeutics.

[6]  R. Eliakim,et al.  Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[7]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[8]  M. Carneiro-Sampaio,et al.  Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin , 2009, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[9]  P. Perre.  Transfer of antibody via mother's milk. , 2003 .

[10]  E. Karita,et al.  Infective and anti-infective properties of breastmilk from HIV-1-infected women , 1993, The Lancet.